Avience Biomedicals
Avience Biomedicals (AVIENCE) share price was ₹270.70 at the 28 Oct 2026 close; market capitalisation ₹148 Cr; sector Healthcare. In the Mar 2026 quarter, revenue rose 5.0% year on year to ₹25.69 Cr and net profit fell 1.2% year on year to ₹4.22 Cr (compared with Mar 2025). Promoters held 64.59% of Avience Biomedicals in Sep 2026, unchanged from Jun 2026.
Key Fundamentals
SMEPrice-based figures as of 29 Oct 2026, 10:33 IST · TTM
Peer Comparison
Healthcare › Healthcare Equipment & Supplies › Medical Equipment & Supplies
| ₹1,462.50 | 47.04 | 14,824 Cr | 4.77 | 0.24% | 10.18% | 13.33% | 2,115 Cr | 313 Cr | |
| ₹26.38 | 69.42 | 1,727 Cr | 3.77 | 0.20% | 8.11% | 12.69% | 373 Cr | 24 Cr | |
| ₹308.25 | 147.49 | 1,640 Cr | 2.58 | 0.66% | 2.26% | 4.82% | 468 Cr | 11 Cr | |
| ₹550.00 | 26.07 | 1,283 Cr | 2.63 | 0.00% | 22.63% | 26.37% | 201 Cr | 34 Cr | |
| ₹178.55 | 31.83 | 983 Cr | 4.04 | 0.00% | 10.83% | 11.51% | 289 Cr | 31 Cr | |
| ₹577.00 | — | 839 Cr | 5.35 | 0.00% | 13.22% | 19.52% | — | — | |
| Avience Biomedicals (this company) | ₹267.00 | — | 146 Cr | 1.62 | 0.00% | 27.86% | 31.13% | — | — |
| Median 7 companies | ₹308.25 | 47.04 | 1,283 Cr | 3.77 | 0.00% | 10.83% | 13.33% | 373 Cr | 31 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.
Tapetide Score
Data-driven rating, 0–100. How it works →
No Tapetide Score has been computed for this stock yet.
Key Insights
Strengths
1- Company has a good return on equity (ROE) track record: 3 Years ROE 37.9%
Weaknesses
1- Company might be capitalizing the interest cost
Technical Indicators
Oscillators
Bearish
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 29.93% · Mar 2026
Quarterly Results
| Particulars | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 24.47 | 26.82 | 25.69 |
| Expenses | 17.86 | 19.57 | 18 |
| Operating Profit | 6.61 | 7.25 | 7.69 |
| OPM % | 27.01% | 27.03% | 29.93% |
| Other Income | 0.46 | 0.06 | 0.23 |
| Interest | 0.69 | 0.65 | 0.89 |
| Depreciation | 0.48 | 0.56 | 0.66 |
| PBT | 5.9 | 6.1 | 6.37 |
| Tax % | 27.63% | 25.74% | 33.75% |
| Net Profit | 4.27 | 4.54 | 4.22 |
| EPS (₹) | 10.59 | 11.26 | 10.47 |
Profit & Loss
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 23.83 | 44.92 | 52.46 |
| Expenses | 19.65 | 33.4 | 37.36 |
| Operating Profit | 4.18 | 11.52 | 15.1 |
| OPM % | 17.54% | 25.65% | 28.78% |
| Other Income | 0.41 | 0.58 | 0.29 |
| Interest | 0.94 | 1.45 | 1.7 |
| Depreciation | 0.62 | 0.88 | 1.22 |
| PBT | 3.03 | 9.77 | 12.47 |
| Tax % | 28.71% | 27.33% | 29.75% |
| Net Profit | 2.16 | 7.1 | 8.75 |
| EPS (₹) | 6.58 | 17.61 | 21.71 |
| Div. Payout % | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 3.28 | 4.03 | 4.03 |
| Reserves | 2.94 | 18.63 | 27.38 |
| Borrowings | 15.13 | 22.16 | 28.93 |
| Other Liabilities | 13.18 | 11.6 | 14.2 |
| Total Liabilities | 34.53 | 56.42 | 74.54 |
| Fixed Assets | 10.25 | 13.1 | 16.06 |
| CWIP | 0.03 | 4.62 | 12.85 |
| Investments | 0.03 | 0.03 | 0.03 |
| Other Assets | 24.22 | 38.67 | 45.6 |
| Total Assets | 34.53 | 56.42 | 74.54 |
Cash Flow
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Operating | 1.02 | 3.39 | 5.91 |
| Investing | -3.9 | -9.54 | -13.27 |
| Financing | 2.93 | 10.21 | 5.42 |
| Net Cash Flow | 0.05 | 4.06 | -1.95 |
| Free Cash Flow | -2.81 | -5.87 | -7.44 |
| CFO/OP | 29 | 36 | 58 |
Ratios
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Debtor Days | 124 | 140 | 146 |
| Inventory Days | 290 | 176 | 218 |
| Days Payable | 130 | 98.06 | 120 |
| Cash Conversion Cycle | 284 | 218 | 244 |
| Working Capital Days | 28.64 | 70.29 | 74.1 |
| ROCE % | — | 34.18% | 26.95% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Avience Biomedicals insights
52 extracted metrics + investor summaries across FY24–FY26.
Documents
Frequently Asked Questions about Avience Biomedicals
What does Avience Biomedicals Ltd do?
Where is Avience Biomedicals Ltd (AVIENCE) listed?
Which sector does Avience Biomedicals Ltd belong to?
What is the market capitalisation of Avience Biomedicals Ltd?
What is the 52-week high and low of Avience Biomedicals Ltd?
What is the Return on Equity (ROE) of Avience Biomedicals Ltd?
Company Information
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AVIENCE.md for Avience Biomedicals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.